Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
Retrieved on:
Wednesday, August 9, 2023
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results and recent updates for the second quarter ended June 30, 2023.
Key Points:
- SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results and recent updates for the second quarter ended June 30, 2023.
- “In parallel, our research organization continues to progress towards a second development candidate nomination, which we expect later this year.
- Assembly Bio’s cash position is projected to fund operations through the third quarter of 2024.
- General and administrative expenses were $5.0 million for the three months ended June 30, 2023, compared to $6.8 million for the same period in 2022.